Survival: 18.0 months     Toxicity Grade: 3     Treatments: Immunotherapy     Drugs:

Country: France     City/State/Province: Marseille     Hospital: Hopital de la Conception     Journal: Link     Date: 11/1998

Description:

Patients: This Phase II study involved 22 patients with malignant pleural mesothelioma. Treatment: The treatment consisted of the intrapleural administration of interleukin-2. (Interleukin-2 is a cytokine or immune system messenger which encourages the proliferation of CD4 cells.) Toxicity: Grade 3 toxicities included cardiovascular, weight gain, sepsis, and cutaneous. Results: The overall median survival time was 18 months.